147 related articles for article (PubMed ID: 10206702)
1. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
[TBL] [Abstract][Full Text] [Related]
2. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region.
Ahlborg N; Ling IT; Howard W; Holder AA; Riley EM
Infect Immun; 2002 Feb; 70(2):820-5. PubMed ID: 11796616
[TBL] [Abstract][Full Text] [Related]
3. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.
Stanisic DI; Martin LB; Liu XQ; Jackson D; Cooper J; Good MF
Infect Immun; 2003 Oct; 71(10):5700-13. PubMed ID: 14500491
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
5. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
Tian JH; Kumar S; Kaslow DC; Miller LH
Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
[TBL] [Abstract][Full Text] [Related]
6. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).
Ahlborg N; Ling IT; Holder AA; Riley EM
Infect Immun; 2000 Apr; 68(4):2102-9. PubMed ID: 10722607
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
Matsumoto S; Yukitake H; Kanbara H; Yamada T
J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
[TBL] [Abstract][Full Text] [Related]
8. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
9. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria.
Wipasa J; Hirunpetcharat C; Mahakunkijcharoen Y; Xu H; Elliott S; Good MF
J Immunol; 2002 Jul; 169(2):944-51. PubMed ID: 12097400
[TBL] [Abstract][Full Text] [Related]
10. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
[TBL] [Abstract][Full Text] [Related]
11. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
Singh B; Cabrera-Mora M; Jiang J; Galinski M; Moreno A
Vaccine; 2010 Mar; 28(14):2580-92. PubMed ID: 20097151
[TBL] [Abstract][Full Text] [Related]
12. Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.
Kawabata Y; Udono H; Honma K; Ueda M; Mukae H; Kadota J; Kohno S; Yui K
Infect Immun; 2002 Nov; 70(11):6075-82. PubMed ID: 12379684
[TBL] [Abstract][Full Text] [Related]
13. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
Alaro JR; Lynch MM; Burns JM
Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
[TBL] [Abstract][Full Text] [Related]
14. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
[TBL] [Abstract][Full Text] [Related]
15. Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice.
Miyata T; Harakuni T; Taira T; Matsuzaki G; Arakawa T
Vaccine; 2012 Jan; 30(5):948-58. PubMed ID: 22119928
[TBL] [Abstract][Full Text] [Related]
16. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice.
Sakai T; Hisaeda H; Nakano Y; Zhang M; Takashima M; Ishii K; Maekawa Y; Matsumoto S; Nitta Y; Miyazaki Ji; Yamamoto S; Himeno K
Vaccine; 2003 Mar; 21(13-14):1432-44. PubMed ID: 12615440
[TBL] [Abstract][Full Text] [Related]
17. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
19. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
20. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.
Daly TM; Long CA
Infect Immun; 1996 Jul; 64(7):2602-8. PubMed ID: 8698485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
